Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7473 - 7480 of 12099 results
False Labeling Lawsuits Get Hung Up On Faulty Damages Models
January 16, 2017| Blog| Viewpoint
FTC Takes Action Against D-Link for Deceptive Practices Endangering the IoT
January 13, 2017| Blog| Viewpoint
Health Care Enforcement Review And 2017 Outlook: Part 1
January 13, 2017| News
FDA Sticks to Its Naming Plan for Biologics and Biosimilars
January 13, 2017| News
When An Arbitration Clause Sounds Permissive But Is Not -- Does "May" Really Mean "Must"?
January 12, 2017| Blog| Viewpoint
Pizza! Pizza!: Little Caesar’s Repeated Term Slogans Are Not a “Family of Marks”
January 12, 2017| Blog| Viewpoint
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress
January 12, 2017| Blog| Viewpoint
Grassley Continues To Press CMS on Medicaid Drug Rebate Classifications: What Will Be the Fallout?
January 12, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Mintz Advises on Equillium, Inc.'s up to $50 Million PIPE
August 15, 2025
Mintz advised the lead placement agent in connection with an up to $50 million private placement by Equillium, Inc. The PIPE was comprised of (i) an initial upfront closing of approximately $30 million in gross proceeds in exchange for approximately 52.6 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), and (ii) the potential for up to an additional $20 million in gross proceeds in exchange for up to approximately 35.1 million shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to achieving specified milestones related to clinical study initiation and share price.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|